Evaluate Vantage's coverage of the virtual Ash 2020 congress.
Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
The lack of clinical progress in Alzheimer's has not put analysts off valuing aducanumab at $10bn.